Sat, 05 Sep 2015 01:16:13 GMT ~ QLT Provides Additional Update on Its Proposed Acquisition of InSite Vision Incorporated
[at noodls] - VANCOUVER, British Columbia, Sept. 4, 2015 (GLOBE NEWSWIRE) -- QLT Inc. (NASDAQ:QLTI) (TSX:QLT) ('QLT' or the 'Company') announces that it has been advised by InSite Vision Incorporated ('InSite') that ...
Fri, 04 Sep 2015 22:16:14 GMT ~ InSite Vision Determines that an Unsolicited Offer from a Global Pharmaceutical Company to Acquire InSite for $0.35 per Share in Cash Constitutes a “Company Superior Proposal”
[at noodls] - InSite Vision Determines that an Unsolicited Offer from a Global Pharmaceutical Company to Acquire InSite for $0.35 per Share in Cash Constitutes a 'Company Superior Proposal' Bidder Favorably Concludes ...
Fri, 04 Sep 2015 21:49:00 GMT ~ InSite Vision Determines that an Unsolicited Offer from a Global Pharmaceutical Company to Acquire InSite for $0.35 per Share in Cash Constitutes a “Company Superior Proposal”
[Business Wire] - InSite Vision Inc. today announced that InSite’s Board of Directors has determined that the previously announced unsolicited offer from a global pharmaceutical company to acquire all outstanding shares of InSite Vision common stock at $0.35 per share in an all-cash transaction constitutes a “Company Superior Proposal” as defined in InSite’s previously announced definitive agreement with QLT Inc.
Link: http://www.otcmarkets.com/stock/INSV/company-info Ticker: $INSV OTC Market Place: OTCQB CIK code: 0000802724 Company name: InSite Vision, Inc. Company website: http://www.insitevision.com Incorporated In: DE, USA
Business Description: InSite Vision is committed to advancing new and superior ophthalmologic products for unmet eye care needs. The Company's lead product is AzaSite*, which targets infections of the eye. AzaSite contains the drug azithromycin, a broad-spectrum antibiotic formulated with DuraSite, InSite Vision's patented drug-delivery vehicle, which offers the benefit of a low-dosing regimen, attractive to both the eye-care patient and physician.AzaSite was launched in the United States in August 2007 by Inspire Pharmaceuticals, InSite Vision's commercial partner for the U.S. and Canada. The company's product development portfolio also includes ISV-502 (AzaSite Plus), which is currently in Phase 3 pivotal trials for the treatment of eyelid infection and inflammation, and additional product candidates leveraging the company's core DuraSite technology platform. InSite has recently advanced two new product candidates for the treatment of eye pain and inflammation into preclinical testing.InSite Vision's strategy includes maximizing AzaSite sales in the U.S. and abroad through close collaboration with marketing partners, seeking development partners for its DuraSite-enabled early-stage product candidates, and applying the company's expertise in ophthalmology to identify, in-license, or acquire promising new product candidates or technologies.Less >>
$INSV share structure
## source: otcmarkets.com
Market Value: $44,203,596 a/o Sep 04, 2015 Shares Outstanding: 131,951,033 a/o Feb 24, 2015 Float: Not Available Authorized Shares: 240,000,000 a/o Feb 12, 2015 Par Value: 0.01
$INSV extra dd links
Company name: InSite Vision, Inc. Company website: http://www.insitevision.com